{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:41:25Z","timestamp":1768318885238,"version":"3.49.0"},"reference-count":27,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"PMU Forschungs- und Innovationszentrum Public Health & Versorgungsforschung (FIZ PH&VF) Talent Pool-Projekts","award":["FIZ-PV-S-25-07-ROO"],"award-info":[{"award-number":["FIZ-PV-S-25-07-ROO"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Psychosis is a frequent and disabling non-motor complication of Parkinson\u2019s disease (PD). Clozapine and quetiapine are widely used in the treatment of Parkinson\u2019s disease psychosis (PDP). We conducted an exploratory study to compare patient experiences with physician prescribing practices. Patients with PDP hospitalized at a university center completed semi-structured interviews on perceived efficacy, adverse effects, and daily functioning. Neurologists and geriatricians attending training sessions completed a structured questionnaire on prescribing patterns, attitudes toward clozapine, and perceived treatment burden. Data were analyzed thematically and triangulated across cohorts. Eleven patients (mean age 81 years; nine treated with quetiapine, two with clozapine) were included. Most quetiapine-treated patients reported persistent hallucinations, sedation, dizziness, and reduced autonomy. Fourteen physicians completed the survey and most preferred quetiapine, citing monitoring logistics and agranulocytosis risk as barriers to clozapine. Overall, patient priorities centered on symptom control and independence, whereas physician decisions emphasized feasibility and safety. Facilitating clozapine monitoring and incorporating patient-reported outcomes into routine care may improve patient-centered PDP management.<\/jats:p>","DOI":"10.3390\/pharmacy14010008","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T09:27:12Z","timestamp":1768296432000},"page":"8","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient and Physician Perspectives on Pharmacotherapy in Parkinson\u2019s Disease Psychosis: A Mixed-Methods Exploratory Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1681-4909","authenticated-orcid":false,"given":"Olaf","family":"Rose","sequence":"first","affiliation":[{"name":"Institute of Pharmacy, Pharmaceutical Biology and Clinical Pharmacy, Paracelsus Medical University, Strubergasse 21, 5020 Salzburg, Austria"},{"name":"Center of Public Health and Health Services Research, Paracelsus Medical University, Strubergasse 21, 5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Hinteregger","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Pharmaceutical Biology and Clinical Pharmacy, Paracelsus Medical University, Strubergasse 21, 5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5950-2692","authenticated-orcid":false,"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Centre for Cognitive Neuroscience, EpiCARE, Christian-Doppler University Hospital, Paracelsus Medical University, 5020 Salzburg, Austria"},{"name":"Paracelsus Medical University Centre for Cognitive Neuroscience, Neuroscience Institute, Christian-Doppler University Hospital, 5020 Salzburg, Austria"},{"name":"Karl Landsteiner Institute of Neurorehabilitation and Space Neurology, 5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6132-8670","authenticated-orcid":false,"given":"Bernhard","family":"Iglseder","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Christian Doppler Klinik, Paracelsus Medical University, Ignaz-Harrer-Stra\u00dfe 79, 5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Pachmayr","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Pharmaceutical Biology and Clinical Pharmacy, Paracelsus Medical University, Strubergasse 21, 5020 Salzburg, Austria"},{"name":"Center of Public Health and Health Services Research, Paracelsus Medical University, Strubergasse 21, 5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8788-9329","authenticated-orcid":false,"given":"Stephanie","family":"Clemens","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Pharmaceutical Biology and Clinical Pharmacy, Paracelsus Medical University, Strubergasse 21, 5020 Salzburg, Austria"},{"name":"Center of Public Health and Health Services Research, Paracelsus Medical University, Strubergasse 21, 5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e080952","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: Modelling study of Global Burden of Disease Study 2021","volume":"388","author":"Su","year":"2025","journal-title":"BMJ"},{"key":"ref_2","first-page":"277","article-title":"Parkinson-Krankheit: Basiswissen","volume":"39","author":"Rose","year":"2016","journal-title":"Med. Monatsschr. Pharm."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41582-023-00918-8","article-title":"Parkinson disease psychosis: From phenomenology to neurobiological mechanisms","volume":"20","author":"Pagonabarraga","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneurol.2010.166","article-title":"A 12-year population-based study of psychosis in Parkinson disease","volume":"67","author":"Forsaa","year":"2010","journal-title":"Arch. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100870","DOI":"10.1016\/j.lanepe.2024.100870","article-title":"The impact of psychiatric comorbidity on Parkinson\u2019s disease outcomes: A systematic review and meta-analysis","volume":"39","author":"Burchill","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/bs.irn.2017.04.005","article-title":"Psychosis in Parkinson\u2019s Disease","volume":"133","author":"Ffytche","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","article-title":"The psychosis spectrum in Parkinson disease","volume":"13","author":"Ffytche","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1080\/14656566.2016.1234609","article-title":"Pimavanserin for the treatment of Parkinson\u2019s disease psychosis","volume":"17","author":"Chendo","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp-2011-300980","article-title":"Visual hallucinations in the differential diagnosis of parkinsonism","volume":"83","author":"Bertram","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/ene.13376","article-title":"The role of neurotransmitters in the development of Parkinson\u2019s disease-related psychosis","volume":"24","author":"Factor","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.socscimed.2008.04.014","article-title":"Caregivers\u2019 experiences of caring for a husband with Parkinson\u2019s disease and psychotic symptoms","volume":"67","author":"Williamson","year":"2008","journal-title":"Soc. Sci. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jamda.2023.04.004","article-title":"Hospitalization and the Risk of Initiation of Antipsychotics in Persons with Parkinson\u2019s Disease","volume":"24","author":"Tiihonen","year":"2023","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.parkreldis.2020.07.021","article-title":"Efficacy and safety of atypical antipsychotics for psychosis in Parkinson\u2019s disease: A systematic review and Bayesian network meta-analysis","volume":"78","author":"Iketani","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Rose, O., Huber, S., Trinka, E., Pachmayr, J., and Clemens, S. (2024). Treatment of Parkinson\u2019s Disease Psychosis-A Systematic Review and Multi-Methods Approach. Biomedicines, 12.","DOI":"10.3390\/biomedicines12102317"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"(1999). Clozapine in drug-induced psychosis in Parkinson\u2019s disease. The French Clozapine Parkinson Study Group. Lancet, 353, 2041\u20132042.","DOI":"10.1016\/S0140-6736(99)00860-0"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S2215-0366(25)00098-7","article-title":"Absolute neutrophil count and adverse drug reaction monitoring during clozapine treatment: Consensus guidelines from a global Delphi panel","volume":"13","author":"Siskind","year":"2026","journal-title":"Lancet Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1756285610389656","article-title":"Quetiapine in the treatment of psychosis in Parkinson\u2019s disease","volume":"3","author":"Shotbolt","year":"2010","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pharmthera.2018.06.012","article-title":"Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences","volume":"192","author":"Aringhieri","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"The Parkinson Study Group (1999). Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N. Engl. J. Med., 340, 757\u2013763.","DOI":"10.1056\/NEJM199903113401003"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4103\/picr.picr_318_23","article-title":"Designing and validating a research questionnaire\u2014Part 2","volume":"15","author":"Ranganathan","year":"2024","journal-title":"Perspect. Clin. Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Boateng, G.O., Neilands, T.B., Frongillo, E.A., Melgar-Qui\u00f1onez, H.R., and Young, S.L. (2018). Best Practices for Developing and Validating Scales for Health, Social, and Behavioral Research: A Primer. Front. Public Health, 6.","DOI":"10.3389\/fpubh.2018.00149"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100891","DOI":"10.1016\/j.jbef.2024.100891","article-title":"Take the aTrain. Introducing an interface for the Accessible Transcription of Interviews","volume":"41","author":"Haberl","year":"2024","journal-title":"J. Behav. Exp. Financ."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Mayring, P. (2022). Qualitative Inhaltsanalyse: Grundlagen und Techniken, Beltz. 13., \u00fcberarbeitete Auflage.","DOI":"10.1007\/978-3-658-37985-8_43"},{"key":"ref_24","first-page":"3","article-title":"Atypical antipsychotics: Sleep, sedation, and efficacy","volume":"6","year":"2004","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.eurpsy.2007.01.1167","article-title":"Sedation is not the opposite of agitation","volume":"22","author":"Kasper","year":"2007","journal-title":"Eur. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Gharabawi, G.M., Greenspan, A., Rupnow, M.F.T., Kosik-Gonzalez, C., Bossie, C.A., Zhu, Y., Kalali, A.H., and Awad, A.G. (2006). Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial. BMC Psychiatry, 6.","DOI":"10.1186\/1471-244X-6-45"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/bs.pbr.2022.01.017","article-title":"Speech dysfunction, cognition, and Parkinson\u2019s disease","volume":"269","author":"Rohl","year":"2022","journal-title":"Prog. Brain Res."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/14\/1\/8\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T09:46:11Z","timestamp":1768297571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/14\/1\/8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["pharmacy14010008"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy14010008","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]}}}